'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial 16-Oct-2023 By Liza Laws Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.